Uzbekistan Digital Health Platform - Integrations
0.1.0 - ci-build
Uzbekistan Digital Health Platform - Integrations
0.1.0 - ci-build
Uzbekistan Digital Health Platform - Integrations - Local Development build (v0.1.0) built by the FHIR (HL7® FHIR® Standard) Build Tools. See the Directory of published versions
| Draft 2026-07-13 holatiga ko‘ra |
{
"resourceType" : "ConceptMap",
"id" : "dhis-observation-component-to-loinc",
"language" : "uz",
"text" : {
"status" : "generated",
"div" : "<div xml:lang=\"uz\" lang=\"uz\"><hr/><p><b>Uzbek</b></p><hr/><p class=\"res-header-id\"><b>Generated Narrative: ConceptMap dhis-observation-component-to-loinc</b></p><a name=\"uz-dhis-observation-component-to-loinc\"> </a><a name=\"uz-hcdhis-observation-component-to-loinc\"> </a><p>Mapping from (not specified) to <a href=\"http://loinc.org/\">All LOINC codes</a></p><br/><p>Mapping from <a href=\"CodeSystem-dhis-observation-component-code-cs.html\">DHIS Observation Component Code CodeSystemversion: 0.1.0)</a> to <code>http://loinc.org</code> (Logical Observation Identifier Names and Codes (LOINC))</p><table class=\"grid\"><tr><td><b>Source Code</b></td><td><b>Relationship</b></td><td><b>Target Code</b></td></tr><tr><td>tub004-0007 (Rifampitsin (1,0 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>18974-6 (Rifampin [Susceptibility])</td></tr><tr><td>tub004-0008 (Izoniazid (0,1 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>18934-0 (Isoniazid [Susceptibility])</td></tr><tr><td>tub004-0009 (Etambutol (5,0 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>18921-7 (Ethambutol [Susceptibility])</td></tr><tr><td>tub004-0010 (Pirazinamid (100 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>18973-8 (Pyrazinamide [Susceptibility])</td></tr><tr><td>tub004-0011 (Levofloksatsin (2,0 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>20629-2 (Levofloxacin [Susceptibility])</td></tr><tr><td>tub004-0012 (Moksifloksatsin (1,0 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>31039-1 (Moxifloxacin [Susceptibility])</td></tr><tr><td>tub004-0013 (Moksifloksatsin (0,25 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>31039-1 (Moxifloxacin [Susceptibility])</td></tr><tr><td>tub004-0014 (Gatifloksatsin (0,25 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>31038-3 (Gatifloxacin [Susceptibility])</td></tr><tr><td>tub004-0015 (Amikatsin (1,0 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>18860-7 (Amikacin [Susceptibility])</td></tr><tr><td>tub004-0016 (Protionamid (2,5 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>100057-9 (Prothionamide [Susceptibility])</td></tr><tr><td>tub004-0017 (Linezolid (1,0 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>29258-1 (Linezolid [Susceptibility])</td></tr><tr><td>tub004-0018 (Klofazimin (1,0 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>23627-3 (Clofazimine [Susceptibility])</td></tr><tr><td>tub004-0019 (Bedaquilin (1,0 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>94274-8 (Bedaquiline [Susceptibility])</td></tr><tr><td>tub004-0020 (Delamanid (0,06 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>93851-4 (Delamanid [Susceptibility])</td></tr><tr><td>tub004-0021 (Pretomanid (1,0 mg/ml))</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#source-is-narrower-than-target\" title=\"source-is-narrower-than-target\">is narrower than</a></td><td>93850-6 (Pretomanid [Susceptibility])</td></tr><tr><td>tub004-0025 (Ethionamide-Prothionamide)</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#related-to\" title=\"related-to\">is related to</a></td><td>18922-5 (Ethionamide [Susceptibility])</td></tr><tr><td>tub004-0022 (Rifampcin)</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>18974-6 (Rifampin [Susceptibility])</td></tr><tr><td>tub004-0028 (Levofloxacin)</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>20629-2 (Levofloxacin [Susceptibility])</td></tr><tr><td>tub004-0029 (Amikacin)</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>18860-7 (Amikacin [Susceptibility])</td></tr><tr><td>tub004-0030 (Kanamycin)</td><td><a href=\"http://hl7.org/fhir/R5/codesystem-concept-map-relationship.html#equivalent\" title=\"equivalent\">is equivalent to</a></td><td>18935-7 (Kanamycin [Susceptibility])</td></tr></table></div>"
},
"url" : "https://terminology.dhp.uz/fhir/integrations/ConceptMap/dhis-observation-component-to-loinc",
"version" : "0.1.0",
"name" : "ObservationComponentToLoinc",
"title" : "Tuberculosis Drug Susceptibility Components to LOINC",
"status" : "draft",
"experimental" : false,
"date" : "2026-07-13T16:58:44+05:00",
"publisher" : "Uzinfocom LLC",
"contact" : [
{
"name" : "Uzinfocom LLC",
"telecom" : [
{
"system" : "url",
"value" : "https://uzinfocom.uz"
},
{
"system" : "email",
"value" : "info@uzinfocom.uz"
}
]
}
],
"description" : "Maps the local DHIS drug-susceptibility-test component codes to their LOINC [Susceptibility] code. Where the relationship is `equivalent` (plain drug-name agents), use the LOINC code directly in resources (see the DHIS Observation Component Code ValueSet); concentration-bearing agents are narrower and keep their local code. Non-drug component codes (interpretations, grading, identification flags) have no LOINC equivalent and are not listed.",
"jurisdiction" : [
{
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "UZ",
"display" : "Uzbekistan"
}
]
}
],
"targetScopeCanonical" : "http://loinc.org/vs",
"group" : [
{
"source" : "https://terminology.dhp.uz/fhir/integrations/CodeSystem/dhis-observation-component-code-cs|0.1.0",
"target" : "http://loinc.org",
"element" : [
{
"code" : "tub004-0007",
"display" : "Rifampitsin (1,0 mg/ml)",
"target" : [
{
"code" : "18974-6",
"display" : "Rifampin [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0008",
"display" : "Izoniazid (0,1 mg/ml)",
"target" : [
{
"code" : "18934-0",
"display" : "Isoniazid [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0009",
"display" : "Etambutol (5,0 mg/ml)",
"target" : [
{
"code" : "18921-7",
"display" : "Ethambutol [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0010",
"display" : "Pirazinamid (100 mg/ml)",
"target" : [
{
"code" : "18973-8",
"display" : "Pyrazinamide [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0011",
"display" : "Levofloksatsin (2,0 mg/ml)",
"target" : [
{
"code" : "20629-2",
"display" : "Levofloxacin [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0012",
"display" : "Moksifloksatsin (1,0 mg/ml)",
"target" : [
{
"code" : "31039-1",
"display" : "Moxifloxacin [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0013",
"display" : "Moksifloksatsin (0,25 mg/ml)",
"target" : [
{
"code" : "31039-1",
"display" : "Moxifloxacin [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0014",
"display" : "Gatifloksatsin (0,25 mg/ml)",
"target" : [
{
"code" : "31038-3",
"display" : "Gatifloxacin [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0015",
"display" : "Amikatsin (1,0 mg/ml)",
"target" : [
{
"code" : "18860-7",
"display" : "Amikacin [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0016",
"display" : "Protionamid (2,5 mg/ml)",
"target" : [
{
"code" : "100057-9",
"display" : "Prothionamide [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0017",
"display" : "Linezolid (1,0 mg/ml)",
"target" : [
{
"code" : "29258-1",
"display" : "Linezolid [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0018",
"display" : "Klofazimin (1,0 mg/ml)",
"target" : [
{
"code" : "23627-3",
"display" : "Clofazimine [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0019",
"display" : "Bedaquilin (1,0 mg/ml)",
"target" : [
{
"code" : "94274-8",
"display" : "Bedaquiline [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0020",
"display" : "Delamanid (0,06 mg/ml)",
"target" : [
{
"code" : "93851-4",
"display" : "Delamanid [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0021",
"display" : "Pretomanid (1,0 mg/ml)",
"target" : [
{
"code" : "93850-6",
"display" : "Pretomanid [Susceptibility]",
"relationship" : "source-is-narrower-than-target"
}
]
},
{
"code" : "tub004-0025",
"display" : "Ethionamide-Prothionamide",
"target" : [
{
"code" : "18922-5",
"display" : "Ethionamide [Susceptibility]",
"relationship" : "related-to"
}
]
},
{
"code" : "tub004-0022",
"display" : "Rifampcin",
"target" : [
{
"code" : "18974-6",
"display" : "Rifampin [Susceptibility]",
"relationship" : "equivalent"
}
]
},
{
"code" : "tub004-0028",
"display" : "Levofloxacin",
"target" : [
{
"code" : "20629-2",
"display" : "Levofloxacin [Susceptibility]",
"relationship" : "equivalent"
}
]
},
{
"code" : "tub004-0029",
"display" : "Amikacin",
"target" : [
{
"code" : "18860-7",
"display" : "Amikacin [Susceptibility]",
"relationship" : "equivalent"
}
]
},
{
"code" : "tub004-0030",
"display" : "Kanamycin",
"target" : [
{
"code" : "18935-7",
"display" : "Kanamycin [Susceptibility]",
"relationship" : "equivalent"
}
]
}
]
}
]
}